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Edited by Maurice MontalAbstract Batrachotoxin is a potent modulator of voltage-gated
sodium channels, leading to irreversible depolarisation of nerves
and muscles, ﬁbrillation, arrhythmias and eventually cardiac
failure. Since its discovery, ﬁeld researchers also reported
numbness after their skin came into contact with this toxin.
Intrigued by this phenomenon, we determined the eﬀect of
batrachotoxin on the voltage-gated sodium channel Nav1.8,
which is considered to be a key player in nociception. As a result,
we discovered that batrachotoxin profoundly modulates this
channel: the inactivation process is severely altered, the voltage-
dependence of activation is shifted towards more hyperpolarised
potentials resulting in the opening of Nav1.8 at more negative
membrane potentials and the ion selectivity is modiﬁed.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Poison Dart frogs (Phyllobates spp.) are often strikingly
coloured anurans, which excrete several alkaloid toxins from
their skin [1] (Fig. 1). Among these excretions is one of the
most potent toxins known in nature, batrachotoxin (BTX) [2].
Close relatives like homobatrachotoxin occur in the skin and
feathers of three passerine bird species of the genus Pitohui and
the Ifrita kowaldi bird endemic to New Guinea (Fig. 1) [3,4].
These toxins are potent modulators of voltage-gated sodium
channels (VGSCs), which orchestrate the generation of action
potentials and are key elements in the signal transduction
process of membranes of neurons and most excitable cells [5–
7]. VGSC modulation by BTX causes an irreversible depo-
larisation of nerves and muscles, ﬁbrillation, arrhythmias and
eventually cardiac failure [8]. Aside from the aforementioned
eﬀects, BTX causes a feeling of numbness upon contact with
human tissue, an eﬀect that remains unexplained [9].
Several reports on native cells and cloned channels have
been published showing that BTX drastically modiﬁes the
gating of VGSCs: this agonist shifts the voltage dependence of
activation to more hyperpolarised voltages. In addition, both* Corresponding author. Fax: +32-163234 05.
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doi:10.1016/j.febslet.2004.10.017fast and slow inactivation processes of the channel are inhib-
ited. Aside from these eﬀects, the ion selectivity is reduced.
BTX-modiﬁed VGSCs display increased permeability for
NHþ4 , K
þ and Csþ ions [10–17].
In the literature, there is evidence that a speciﬁc VGSC plays
an important role in nociception, namely Nav1.8 (Scn10A).
Nav1.8 is expressed in peripheral neurons such as the small
diameter nociceptor neurons of dorsal root ganglia (DRG)
that originate in aﬀerent nociceptive ﬁbres such as the C-ﬁbres
and Ad ﬁbres [18–22]. Behavioural studies on Nav1.8 null
mutant mice have shown that Nav1.8 plays an important role
in the detection of noxious stimuli [23]. Until now, this chal-
lenging tetrodotoxin (TTX)-resistant VGSC still largely re-
mains terra incognita since there are only a few, not very potent
or selective modulators of this VGSC described [24–26]. For
instance, widely used local anaesthetics and class I anti-ar-
rhythmics, like lidocaine and tetracaine, block Nav1.8 [27,28].
The synthetic vincamine derivative, vinpocetine, produces a
concentration- and state-dependent inhibition of Nav1.8
channels expressed in a DRG-derived cell line [26]. Recently,
John and co-workers reported that the novel anticonvulsant
drug lamotrigine and a range of structural analogues block
both Nav1.8 and other TTX-resistant VGSCs [29]. A com-
parative study of the action of tolperison on diﬀerent VGSCs
has revealed that this organic drug preferentially blocks
Nav1.8 at high micromolar concentrations [30].
Here, we wanted to elucidate the analgesic eﬀect (numbness)
of BTX and, therefore, studied its eﬀect on Nav1.8 co-
expressed with the b1 subunit (Nav1.8/b1) in Xenopus laevis
oocytes. In addition, since there are only a few modulators
known for this VGSC, it is an interesting target to screen for
novel ligands.2. Materials and methods
For this study, capped cRNAs were synthesised from the linearised
plasmids, Nav1.8/pSP64T and b1/pSP64T, and injected into oocytes
harvested from anaesthetised female Xenopus laevis frogs according to
established procedures [31–33]. Oocytes were injected with 50 nl of
cRNA at a concentration of 1 ng nl1. The solution used for incu-
bating the oocytes contained (in mM): 96 NaCl, 2 KCl, 1.8 CaCl2, 2
MgCl2 and 5 HEPES (pH 7.4), supplemented with 50 mg l
1 genta-
mycin sulfate and 180 mg l1 theophyllin.
Two-electrode voltage-clamp (TEVC) recordings were performed at
room temperature (18–22 C) using a GeneClamp 500 ampliﬁer con-
trolled by a pClamp data acquisition system (Axon instruments, USA).
Whole-cell currents from oocytes were recorded 4 days after injection.
Currents were sampled at 10 kHz and ﬁltered at 2 kHz using a four-
pole low-pass Bessel ﬁlter. Leak subtraction was performed using a P/4ation of European Biochemical Societies.
Fig. 1. Left panel: Phyllobates terribilis; right panel: Pitohui dichrous;
lower panel: structure of batrachotoxin (R1) or homobatrachotoxin
(R2).
246 F. Bosmans et al. / FEBS Letters 577 (2004) 245–248protocol. The voltage protocols are shown in the ﬁgures. All of the
measurements were performed in control conditions and in the pres-
ence of BTX at concentrations ranging from 500 nM to 10 lM. The
displayed data in Fig. 2 for toxin conditions were recorded after a 900
pulse train experiment at a frequency of 1 Hz.Fig. 2. (A) Representative current traces in response to the voltage
protocol (inset). Displayed data in the presence of BTX were recorded
after a 900 pulse train experiment, each lasting 2 s using a frequency of
1 Hz. From a holding potential of )90 mV, a 50 ms pulse was given to
+30 mV (part I) corresponding to the maximum Naþ inﬂux of the
unaﬀected Nav1.8/b1. Next, a 50 ms pulse to )10 mV (part II) evoked a
transient deactivation response. After 50 ms at +30 mV in the presence
of BTX, the open channel probability is very high caused by the in-
hibition of the inactivation process. As a consequence, the jump to )10
mV causes an initial increase of inward Naþ current due to the in-
creased driving force (this is not instantaneous due to the sluggishness
of TEVC when measuring oocytes). Next, Nav1.8/b1 starts to deacti-
vate at )10 mV which is rather slow and which causes the current
decay over the next 25 ms. The ensuing jump to )120 mV (Part III)
reveals a faster and complete deactivation. In part IV, a pulse is given
to )20 mV in order to reveal a shift in the current–voltage relationship
(I–V curve). In control conditions, Nav1.8/b1 is not yet activated at
)20 mV so there is no current visible. In the presence of BTX, Naþ
ions are passing through even at )20 mV. (B) Corresponding current–
voltage relationship (left panel) before (j) and after addition of 5 lM
(d) and 10 lM (m) BTX. Current traces were evoked using 50 ms step
depolarisations of 10 mV to a voltage range between )70 and 70 mV
from a holding potential of )90 mV. The arrow indicates the shift in
Erev. (C) Superimposed graphics of the corresponding activation and
steady-state inactivation curves. Current traces for the inactivation
protocol were evoked by 50 ms depolarisations from )120 mV to 0 mV
followed by a 50 ms pulse to +30 mV, from a holding potential of )90
mV. As indicated by the arrows, BTX clearly shifts the activation curve
(horizontal arrow) to more negative potentials and inhibits the inac-
tivation process (vertical arrow).
cCurve manipulations were performed using pClamp8 (Axon In-
struments) and Origin software (Microcal, USA). Voltage-dependence
of activation was determined from the I–V curves and the reversal
potential was measured experimentally for each oocyte. The voltage
dependence of relative current (activation and fast inactivation) was ﬁt
by a Boltzmann function.
BTX was kindly provided by John Daly (N.I.H., USA). The mo-
lecular weight was checked on a LCQ Deca XP iontrap mass spec-
trometer (Finnigan Corp., USA).3. Results and discussion
BTX radically and irreversibly aﬀects Nav1.8/b1. Fig. 2A
shows representative current traces in response to voltage
steps. Parts I and IV clearly show that Nav1.8/b1 does not
inactivate in the presence of 10 lM BTX, illustrating that the
inactivation process is severely altered. Fig. 2B shows the
corresponding current–voltage (I–V) relation and Fig. 2C
displays the steady-state activation and inactivation curves.
The voltage-dependence of activation is shifted towards more
hyperpolarised potentials, resulting in the opening of Nav1.8/
Table 1








Control 57.3 2.9 2.9 5.1 5.1 0.4 100
+5 lM BTX 52.4 4.7 )9.1 7.7 9.6 1.1 218 28
+ 10 lM BTX 46.2 2.9 )11.7 4.9 10.4 1.3 427 105
Pooled data from 4–6 oocytes. AUC, area under the curve and k, slope
factor.
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voltage of half-maximal activation (V1=2) shifted towards more
hyperpolarised voltages with 12.0 mV when 5 lM BTX was
applied ðn ¼ 6Þ and with 14.8 mV in the presence of 10 lM
BTX ðn ¼ 4Þ (Table 1). As can be seen in part IV of Fig. 2A,
Nav1.8/b1 activates at )20 mV under the inﬂuence of BTX,
whereas in control conditions the channels are still closed. As a
result of the total loss of inactivation and the leftward shift of
the activation curve, the Naþ ion inﬂux increases dramatically.
A clear marker to demonstrate this is the area under the I–V
curve (AUC) (Fig. 2B). Compared to the control situation, the
AUC increases with 427% when 10 lM BTX is present
(n ¼ 4, Table 1). BTX also changes the ion selectivity as in-
dicated by the shift in the reversal potentials (Erev) (Fig. 2B).
An average hyperpolarising shift of 5.0 mV is present when 5
lM BTX is added ðn ¼ 6Þ and a shift of 11.1 mV was noted in
the presence of 10 lM BTX ðn ¼ 4Þ (Table 1). So both the
gating and selectivity of Nav1.8 are aﬀected by BTX, with the
eﬀect on inactivation being the most drastic. Lower concen-
trations were also tested and we observed that 1 lM of BTX,
measured after a 900 pulse train experiment at a frequency of 1
Hz, already starts to aﬀect Nav1.8/b1. At this concentration, a
small initial block of the current is seen, which is soon followed
by an inﬂux of Naþ ions caused by the inhibition of the in-
activation. In addition, the activation is clearly shifted to more
hyperpolarised voltages. In order to simulate neurons in living
organisms, which have a higher ﬁring rate than 1 Hz (e.g., 20–
50 Hz), we also tested higher frequency pulse trains. At 10 Hz,
we noticed that lower concentrations (500 nM) cause eﬀects
that are related to higher concentrations at 1 Hz (data not
shown). Hence, we believe that in vivo the eﬀects of BTX may
be as catastrophic at even lower concentrations.
Now, how can we tie these results to an analgesic eﬀect? A
general idea about an ideal painkiller is a compound that
blocks Nav1.8 in a use-dependent way (e.g., lidocaine). Here,
we discuss how a compound like BTX, which does not
simply block but profoundly modulates Nav1.8, can also
cause an analgesic eﬀect. It is known from disease-associated
mutations that alterations in either a channel’s selectivity or
gating alter the electrical excitability of the cell. In practice,
functional studies of mutant channels have shown that the
primary defect is usually an alteration in gating and that for
sodium channelopathies the gating defects tend to increase
the likelihood of mutant Naþ channels being open. Such
gating defect will depolarise the cells, which may either cause
hyperexcitability (as in myotonia) by triggering spurious ac-
tion potentials or chronically depolarise the cell to a re-
fractory unexcitable state (as in paralysis). Computer
simulations in a model cell demonstrated that 2% of
non-inactivating Naþ channels cause a myotonic response,
however, a slightly larger proportion of non-inactivatingchannels (3% or more) results in paralysis [34]. BTX causes a
dose-dependent increase in the amplitude of TTX-resistant
Naþ currents (Nav1.8/b1), accompanied by a left-ward shift
in the voltage-dependence of activation. Furthermore, BTX
causes an irreversible dramatic decrease in inactivation and
deactivation rate of Nav1.8/b1 (see Fig. 2, panel II). The
resulting persistent inward Naþ current will lead to a sus-
tained depolarisation of the cell membrane in vivo. As a
consequence, the remaining VGSCs that were not aﬀected by
BTX will be trapped in the inactivated state, resulting in the
loss of electrical excitability of nociceptor neurons.
To conﬁrm this analgesic eﬀect of BTX, a preliminary small
scale clinical experiment was conducted in our laboratory. In a
blind study, three volunteers applied an ointment containing
BTX and a placebo on their hands. This was repeated once
with two diﬀerent concentrations (5 and 25 lg per 100 g of
ointment), which are far below the estimated lethal blood
concentrations (approximately 5–200 lg per adult). An initial
tingling sensation followed by a feeling of numbness was
clearly noticed when the ointment with BTX was applied. The
eﬀect lasted for over 30 min, was reversible and did not cause
any side-eﬀects.
In conclusion, BTX, the ﬁrst profound modulator of Nav1.8,
causes nociceptive neurons to go into arrest, resulting in the
inhibition of action potential trains. We believe that this is the
main reason for the feeling of numbness when human tissue
comes into contact with BTX. We think that this trademark
makes BTX eligible for exploitation in topical applications in
order to inhibit the propagation of pain stimuli.
Acknowledgements: We thank the following persons: John N. Wood,
Univ. College London, UK for sharing Nav1.8; S.H. Heinemann,
Friedrich-Schiller-Universit€at Jena, Germany for sharing the b1 sub-
unit; John Daly, N.I.H., USA for providing batrachotoxin; Jack
Dumbacher for letting us use the Pitohui picture and Stephen C.
Cannon for helpful discussions. C.M. is a postdoctoral research fellow
(postdoctoraal onderzoeker) of the Fund for Scientiﬁc Research –
Flanders (F.W.O.-Vlaanderen). This work was also supported by grant
G.0081.02 (F.W.O. Vlaanderen).References
[1] Daly, J.W. (1998) Thirty years of discovering arthropod alkaloids
in amphibian skin. J. Nat. Prod. 61, 162–172.
[2] Daly, J.W., Myers, C.W., Warnick, J.E. and Albuquerque, E.X.
(1980) Levels of batrachotoxin and lack of sensitivity to its action
in poison-dart frogs (Phyllobates). Science 208, 1383–1385.
[3] Dumbacher, J.P., Beehler, B.M., Spande, T.F., Garraﬀo, H.M.
and Daly, J.W. (1992) Homobatrachotoxin in the genus Pitohui:
chemical defense in birds? Science 258, 799–801.
[4] Dumbacher, J.P., Spande, T.F. and Daly, J.W. (2000) Batrach-
otoxin alkaloids from passerine birds: a second toxic bird genus
(Ifrita kowaldi). from New Guinea. Proc. Natl. Acad. Sci. USA
97, 12970–12975.
[5] Catterall, W.A. (2000) From ionic currents to molecular mecha-
nisms: the structure and function of voltage-gated sodium
channels. Neuron 26, 13–25.
[6] Goldin, A.L., Barchi, R.L., Caldwell, J.H., Hofmann, F., Howe,
J.R., Hunter, J.C., Kallen, R.G., Mandel, G., Meisler, M.H.,
Netter, Y.B., Noda, M., Tamkun, M.M., Waxman, S.G., Wood,
J.N. and Catterall, W.A. (2000) Nomenclature of voltage-gated
sodium channels. Neuron 28, 365–368.
[7] Yu, F.H., Westenbroek, R.E., Silos-Santiago, I., McCormick,
K.A., Lawson, D., Ge, P., Ferriera, H., Lilly, J., DiStefano, P.S.,
Catterall, W.A., Scheuer, T. and Curtis, R. (2003) Sodium channel
beta4, a new disulﬁde-linked auxiliary subunit with similarity to
beta2. J. Neurosci. 23, 7577–7585.
248 F. Bosmans et al. / FEBS Letters 577 (2004) 245–248[8] Albuquerque, E.X., Daly, J.W. and Witkop, B. (1971) Batrach-
otoxin: chemistry and pharmacology. Science 172, 995–1002.
[9] Milius, S. (2001) Poison birds copy ‘don’t touch’ feathers. Sci.
News 160, 214.6–214.610.
[10] Li, H.L., Hadid, D. and Ragsdale, D.S. (2002) The batrach-
otoxin receptor on the voltage-gated sodium channel is
guarded by the channel activation gate. Mol. Pharmacol. 61,
905–912.
[11] Linford, N.J., Cantrell, A.R., Qu, Y., Scheuer, T. and Catterall,
W.A. (1998) Interaction of batrachotoxin with the local anesthetic
receptor site in transmembrane segment IVS6 of the voltage-gated
sodium channel. Proc. Natl. Acad. Sci. USA 95, 13947–13952.
[12] Ulbricht, W. (1998) Eﬀects of veratridine on sodium currents and
ﬂuxes. Rev. Physiol. Biochem. Pharmacol. 133, 1–54.
[13] Wang, S.Y., Barile, M. and Wang, G.K. (2001) Disparate role of
Naþ channel D2-S6 residues in batrachotoxin and local anesthetic
action. Mol. Pharmacol. 59, 1100–1107.
[14] Wang, S.Y. and Wang, G.K. (2003) Voltage-gated sodium
channels as primary targets of diverse lipid-soluble neurotoxins.
Cell Signal. 15, 151–159.
[15] Bartels-Bernal, E., Rosenberry, T.L. and Daly, J.W. (1977) Eﬀect
of batrachotoxin on the electroplax of electric eel: evidence for
voltage-dependent interaction with sodium channels. Proc. Natl.
Acad. Sci. USA 74, 951–955.
[16] De Leon, L. and Ragsdale, D.S. (2003) State-dependent access to
the batrachotoxin receptor on the sodium channel. Neuroreport
14, 1353–1356.
[17] Wang, S.Y. and Wang, G.K. (1998) Point mutations in segment I-
S6 render voltage-gated Naþ channels resistant to batrachotoxin.
Proc. Natl. Acad. Sci. USA 95, 2653–2658.
[18] Akopian, A.N., Sivilotti, L. and Wood, J.N. (1996) A tetrodo-
toxin-resistant voltage-gated sodium channel expressed by sensory
neurons. Nature 379, 257–262.
[19] Baker, M.D. and Wood, J.N. (2001) Involvement of Naþ channels
in pain pathways. Trends Pharmacol. Sci. 22, 27–31.
[20] Julius, D. and Basbaum, A.I. (2001) Molecular mechanisms of
nociception. Nature 413, 203–210.
[21] Renganathan, M., Cummins, T.R. and Waxman, S.G. (2001)
Contribution of Nav1.8 sodium channels to action potential
electrogenesis in DRG neurons.J. Neurophysiology 86, 629–
640.
[22] Tate, S., Benn, S., Hick, C., Trezise, D., John, V., Mannion, R.J.,
Costigan, M., Plumpton, C., Grose, D., Gladwell, Z., Kendall, G.,
Dale, K., Bountra, C. and Woolf, C.J. (1998) Two sodium
channels contribute to the TTX-R sodium current in primary
sensory neurons. Nat. Neurosci. 1, 653–655.[23] Akopian, A.N., Souslova, V., England, S., Okuse, K., Ogata, N.,
Ure, J., Smith, A., Kerr, B.J., McMahon, S.B., Boyce, S., Hill, R.,
Stanfa, L.C., Dickenson, A.H. and Wood, J.N. (1999) The
tetrodotoxin-resistant sodium channel SNS has a specialized
function in pain pathways. Nat. Neurosci. 2, 541–548.
[24] Middleton, R.E., Warren, V.A., Kraus, R.L., Hwang, J.C., Liu,
C.J., Dai, G., Brochu, R.M., Kohler, M.G., Gao, Y.D., Garsky,
V.M., Bogusky, M.J., Mehl, J.T., Cohen, C.J. and Smith, M.M.
(2002) Two tarantula peptides inhibit activation of multiple
sodium channels. Biochemistry 41, 14734–14747.
[25] Weiser, T. and Wilson, N. (2002) Inhibition of tetrodotoxin
(TTX)-resistant and TTX-sensitive neuronal Naþ channels by the
secretolytic ambroxol. Mol. Pharmacol. 62, 433–438.
[26] Zhou, X., Dong, X.W., Crona, J., Maguire, M. and Priestley, T.
(2003) Vinpocetine is a potent blocker of rat NaV1.8 tetrodotoxin-
resistant sodium channels. J. Pharmacol. Exp. Ther. 306, 498–504.
[27] Brau, M.E., Dreimann, M., Olschewski, A., Vogel, W. and
Hempelmann, G. (2001) Eﬀect of drugs used for neuropathic pain
management on tetrodotoxin-resistant Naþ currents in rat sensory
neurons. Anesthesiology 94, 137–144.
[28] Chevrier, P., Vijayaragavan, K. and Chahine, M. (2004) Diﬀer-
ential modulation of Nav1.7 and Nav1.8 peripheral nerve sodium
channels by the local anesthetic lidocaine. Br. J. Pharmacol. 142,
576–584.
[29] John, V.H., Main, M.J., Powell, A.J., Gladwell, Z.M., Hick, C.,
Sidhu, H.S., Clare, J.J., Tate, S. and Trezise, D.J. (2004)
Heterologous expression and functional analysis of rat Nav1.8
(SNS). voltage-gated sodium channels in the dorsal root ganglion
neuroblastoma cell line ND7–23. Neuropharmacology 46, 425–
438.
[30] Hofer, D., Lohberger, B., Steinecker-Frohnwieser, B. and
Schreibmayer, W. (2004) A comparative study of the action of
tolperison on diﬀerent voltage dependent sodium channel iso-
forms. Biophys. J. 86, 118A.
[31] Bosmans, F., Aneiros, A. and Tytgat, J. (2002) The sea anemone
Bunodosoma granulifera contains surprisingly eﬃcacious and
potent insect-selective toxins. FEBS Lett. 532, 131–134.
[32] Liman, E.R., Tytgat, J. and Hess, P. (1992) Subunit stoichiometry
of a mammalian Kþ channel determined by construction of
multimeric cDNAs. Neuron 9, 861–871.
[33] Souslova, V.A., Fox, M., Wood, J.N. and Akopian, A.N. (1997)
Cloning and characterization of a mouse sensory neuron tetrodo-
toxin-resistant voltage-gated sodium channel gene, Scn10a. Ge-
nomics 41, 201–209.
[34] Cannon, S.C. (2001) Voltage-gated ion channelopathies of the
nervous system. Clin. Neurosci. Res. 1, 104–117.
